Exclusive

Most Read

Covid Clinical Trials

Exclusive By Matthew Herper and Erin Riglin

Data show panic and disorganization dominate the study of Covid-19 drugs

Parkinson's cell transplant

Exclusive By Sharon Begley

A secret experiment revealed: In a medical first, doctors treat Parkinson’s with a novel brain cell transplant

abbott labs/trump

Exclusive By Matthew Herper

Rapid coronavirus test, commonly used in U.S., may miss infections in some situations

remdesivir antiviral drug

Exclusive By Adam Feuerstein and Matthew Herper

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

NY phlebotomist

Exclusive By Matthew Herper

Inside the NIH’s controversial decision to stop its big remdesivir study

Virus Outbreak Nebraska Testing

Exclusive By Sharon Begley

Many states are far short of Covid-19 testing levels needed for safe reopening, new analysis shows

OC Phases

Exclusive By Shraddha Chakradhar and Casey Ross

The history of OxyContin, told through unsealed Purdue documents

Prescription pill bottles

Exclusive By Erin Brodwin

Eyeing an IPO, Hims expands further into virtual mental health care

All Coverage

AstraZeneca signage

Exclusive By Rebecca Robbins, Adam Feuerstein, and Helen Branswell

AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.

Stephen Ubl

Exclusive By Nicholas Florko and Lev Facher

PhRMA scrambles to respond to Trump’s drug pricing ultimatum, as Monday deadline looms

advertisement

Mask illustration for card

Exclusive By Helen Branswell, Kate Sheridan, Casey Ross, and Andrew Joseph

The Trump administration haphazardly gave away millions of Covid-19 masks — to schools, broadcasters, and large corporations

FDA stop sign

Exclusive By Nicholas Florko

FDA’s reopening plan will keep biologics labs shuttered far longer than other government labs

Special Report By Lev Facher

Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus

Eric Hargan

Exclusive By Nicholas Florko

In unusual arrangement, deputy HHS secretary’s wife has been lobbying the agency on behalf of health care companies

antibiotics/teal background

Exclusive By Ed Silverman

Pharma giants to unveil major $1 billion venture to push novel antibiotics

hydroxychloroquine pills & bottle

Exclusive By Matthew Herper and Kate Sheridan

Researcher involved in retracted Lancet study has faculty appointment terminated, as details in scandal emerge

glass vials/conveyor belt

Exclusive By Eric Boodman

Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals

Dr. Michelle McMurry-Heath

Exclusive By Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

Rick Bright

Exclusive By Nicholas Florko

Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic

licensing agreement UCSF & Google_1

Exclusive By Rebecca Robbins

Contract offers unprecedented look at Google deal to obtain patient data from the University of California

Robert Redfield

Exclusive By Helen Branswell

CDC director: More person-to-person coronavirus infections in U.S. likely, but containment still possible

Jorge Conde Andreessen Horowitz

Exclusive By Erin Brodwin

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

Mike Ryan

Exclusive By Helen Branswell

Top WHO official says it’s not too late to stop the new coronavirus outbreak

Big data concept illustration

Exclusive By Rebecca Robbins

Medical data startup Syapse cuts 10% of workforce as it prioritizes data analytics and insights

headquarters of Verily Life Sciences

Exclusive By Erin Brodwin

Verily tangos at JPM with a health tech partner — and steps on a few toes

SHATTERED DIGIPILL

Exclusive By Rebecca Robbins

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels

Purdue docs

Exclusive By Casey Ross

Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show

George Church

Exclusive By Sharon Begley

Citing ‘nerd tunnel vision,’ biologist George Church apologizes for contacts with Jeffrey Epstein

U.S. Capitol

Exclusive By Nicholas Florko

PhRMA’s top lobbyist will leave at the end of August

Dr. Feng Zhang Broad Inst

Exclusive By Sharon Begley

The latest CRISPR patent fight is on. So is the mudslinging

MilliporeSigma sign

Exclusive By Sharon Begley

Fight for coveted CRISPR patents gets knottier, as MilliporeSigma makes new claims

Sean Parker reflection

Heavyweights By Rebecca Robbins

Billionaire Sean Parker is nerding out on cancer research. Science has never seen anyone quite like him

Jennifer Doudna - Genome Editing Conference

Exclusive By Matthew Herper

GSK partners with CRISPR pioneer Doudna to search for new drugs